Cardlytics (CDLX)
(Delayed Data from NSDQ)
$3.29 USD
+0.23 (7.52%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.28 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.29 USD
+0.23 (7.52%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.28 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Zacks News
Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
F5 Networks, Cardlytics, Sunrun, Canadian Solar and ReneSola highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
F5 Networks, Cardlytics, Sunrun, Canadian Solar and ReneSola highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Cardlytics (CDLX)
by Jeremy Mullin
Bulls do damage control after poor earnings guide.
New Strong Sell Stocks for August 27th
by Zacks Equity Research
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
Cardlytics (CDLX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of -11.43% and -6.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cardlytics (CDLX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of -21.43% and 2.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 42.86% and 17.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cardlytics (CDLX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics, Inc. (CDLX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 26.92% and -5.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cardlytics, Inc. (CDLX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics Inc (CDLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics Inc (CDLX) delivered earnings and revenue surprises of -18.18% and 5.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What Makes Cardlytics, Inc. (CDLX) a New Strong Buy Stock
by Zacks Equity Research
Cardlytics, Inc. (CDLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Is (CDLX) Outperforming Other Business Services Stocks This Year?
Cardlytics, Inc. (CDLX) Q4 Earnings Top Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 125.00% and -0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics, Inc. (CDLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verisk (VRSK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Verisk's (VRSK) fourth-quarter 2019 earnings and revenues are likely to have increased year over year.
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd
Will Cardlytics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cardlytics.
Here's Why Cardlytics, Inc. (CDLX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Cardlytics, Inc. (CDLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardlytics, Inc. (CDLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardlytics, Inc. (CDLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cardlytics, Inc. (CDLX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardlytics, Inc. (CDLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardlytics, Inc. (CDLX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardlytics, Inc. (CDLX) delivered earnings and revenue surprises of 120.00% and 13.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Cardlytics, Inc. (CDLX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cardlytics, Inc. (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardlytics, Inc. (CDLX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardlytics, Inc. (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).